Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:13 PM
Ignite Modification Date: 2025-12-24 @ 4:13 PM
NCT ID: NCT00505466
Eligibility Criteria: Inclusion Criteria: 2.0 Genetic testing Members of families who have participated in the p53 project through Dr. Strong's lab are eligible, via protocol P90-001. There are at least 145 kindreds including at least 800 participants living who may be at risk of carrying a p53 germline mutation. The participants must provide an informed consent and be 18 years or older. We will include English and non-English speaking participants. For non-English speaking participants to be recruited, the consent documents has been translated into the language of the target population in accordance with the IRB procedures. 2.1 Parents Attitudes toward testing children at risk for TP53 mutations For the survey portion of this study, we will invite individuals who 1) are already enrolled in the P90-001 study), 2) have been known to carry a germline p53 mutation, and 3) have children who are less than 27 years old. Patients who agree to enroll in the survey portion of the study will be presented with a consent statement and a printed copy of the survey along with a postage-paid envelope which they can return (either by mail or in person) at their convenience. 2.2 Psychosocial impact of participating in LFS screening 1. Adults who have undergone genetic testing and have a confirmed p53 mutation 2. Adults participating in LFS screening program Exclusion Criteria: N/A
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Study: NCT00505466
Study Brief:
Protocol Section: NCT00505466